1. Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McEniry D, Zhou XJ, Chao G, Fang C, Fielman B, Myers M, Brown N (2004) Final phase I/II trial results for NM283, a new poly-merase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 40 Suppl 1:726
2. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T, Miyake S (2005) Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43(4):623–629
3. Barreiro P, Soriano V, Casas E, Gonzalez-Lahoz J (2002) Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. Aids 16(2):245–249
4. Barreiro P, Jimenez-Nacher I, Garcia B, Garcia-Benayas T, Rivas P, Soriano V (2005) Nucle-oside/nucleotide backbones for the treatment of HIV infection. Curr Opin Investig Drugs 6(8):812–822
5. Barreiro P, del Romero J, Leal M, Hernando V, Asencio R, de Mendoza C, Labarga P, Nunez M, Ramos JT, Gonzalez-Lahoz J, Soriano V (2006) Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 43(3):324–326